Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
